Oncology
Refine Search
Pharmaceutical
US biopharma company Galmed Pharmaceuticals has entered into a research collaboration with Virginia Commonwealth University to investigate its lead candidate Aramchol (arachidyl amido cholanoic acid) as a potential solution to drug resistance in gastrointestinal cancers. 17 April 2025
Biotechnology
BigHat Biosciences, a Californian biotech with a machine learning (ML)-guided antibody discovery and development platform, has announced a strategic collaboration with US pharma major Eli Lilly. 17 April 2025
Biotechnology
US cancer drug developer Werewolf Therapeutics today announced the appointment of Steven Bloom as chief business officer (CBOP. 17 April 2025
Pharmaceutical
French drugmaker Ipsen today presented sales for the first quarter of 2025. The company did not release any earnings figures. 16 April 2025
Pharmaceutical
Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results. 15 April 2025
Biotechnology
Spanish biotech Reveal Genomics has formed a strategic partnership with oncology firm Ona Therapeutics to support the clinical development of ONA-255, a novel antibody-drug conjugate designed to target therapy-resistant tumor cells in advanced solid cancers. 15 April 2025
Biosimilars
Shares of California-based Coherus BioSciences (Nasdaq: CHRS) rose more than 5% to $0.88 in pre-market activity today as it completed a transformative transaction. 14 April 2025
Biotechnology
The European Commission has approved Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT), Swiss pharma giant Roche announced this morning. 14 April 2025
Pharmaceutical
Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in Japan. US biotech firm Cartesian Therapeutics released positive Phase IIb data on its Descartes-08 in myasthenia gravis. The US Appeal Court gave a favorable ruling on Indian drugmaker Sun pharmaceuticals’ alopecia drug Leqselvi. Also of note, the US Food and Drug Administration (FDA) last week approved Bristol Meyers Squibb’s checkpoint therapy Opdivo plus Yervoy. 13 April 2025
Biotechnology
Johnson & Johnson has announced new data from an analysis modelling long-term progression free survival (PFS) in transplant eligible (TE) and transplant ineligible (TIE) newly diagnosed multiple myeloma (NDMM) patients given Darzalex (daratumumab)-subcutaneous (SC) therapy alongside bortezomib, lenalidomide and dexamethasone (VRd). 11 April 2025
Biotechnology
US biotech giant Amgen today announced a significant breakthrough with its global Phase III DeLLphi-304 clinical trial evaluating Imdelltra (tarlatamab-dlle). 11 April 2025
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Truqap (capivasertib) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread. 11 April 2025
Biotechnology
US biotech Atossa Therapeutics has entered into a research collaboration with China-backed Nona Biosciences, aiming to identify next-generation antibody therapies for breast cancer using Nona’s proprietary platform technology. 10 April 2025
Pharmaceutical
The UK’s National Institute of Health and Care Excellence (NICE) has recommended erdafitinib, trade name Balversa and manufactured by Johnson & Johnson, for some adult patients in England. 10 April 2025
Biotechnology
Solu Therapeutics, a US biotech developing therapies to eliminate disease-driving cells in cancer, immunology and other therapeutic areas, has announced the successful completion of a $41 million Series A financing. 10 April 2025
Biotechnology
Privately-held Finland-based Valo Therapeutics (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its chief executive (CEO) of its Helsinki headquarters and Naples, Italy, subsidiary. 9 April 2025
Biotechnology
Myricx Bio, a UK biotech focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is expanding its team. 8 April 2025
Biotechnology
Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting. 8 April 2025
Biotechnology
Following hot on the heels of Monday’s European Commission EC approval of an indication extension for Johnson & Johnson’s Darzalex (daratumumab) for the treatment of adult patients with newly diagnosed multiple myeloma, comes a second EC approval today – this time in lung cancer. 8 April 2025
Biotechnology
China-based biotech DualityBio has named Hua Mu as its global chief medical officer, as the company prepares to ramp up its international clinical development efforts and advance toward key capital market milestones. 7 April 2025
Biosimilars
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea-based Celltrion’s denosumab biosimilar products, Amgen brands Prolia and Xgeva. 29 January 2025
Biotechnology
Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug failed to improve survival in a Phase II trial. 29 January 2025
Pharmaceutical
Independent French drugmaker Servier, which is governed by a foundation, has published its 2023/24 financial year results and reflected on the major milestones of the year. 29 January 2025
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) has presented attention-grabbing positive Phase III results from a radiopharmaceutical clinical trial. 28 January 2025
Pharmaceutical
Massachusetts-based radiopharmaceutical company Lantheus has announced its plans to acquire clinical-stage radiopharma developer Evergreen Theragnostics in a deal worth up to $1 billion. 28 January 2025
Biotechnology
The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. 28 January 2025
Biotechnology
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the USA as the first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies. 28 January 2025
Biotechnology
Shares in Swiss pharma giant Roche were more than 1% higher on Tuesday afternoon, following the announcement of positive top-line results from the overall survival (OS) analysis of the Phase III INAVO120 study. 28 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for Welireg (belzutifan), Merck & Co’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. 28 January 2025
Pharmaceutical
Taiho Oncology has presented real-world data highlighting the benefits of combining Lonsurf (trifluridine/tipiracil) with bevacizumab for metastatic colorectal cancer. 27 January 2025
Biotechnology
Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima (lenvatinib), Eisai’s orally available multiple receptor tyrosine kinase inhibitor (TKI), alongside chemotherapy, as a first-line treatment of locally-advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal adenocarcinoma. 27 January 2025
Biotechnology
Chinese biopharma CStone Pharmaceuticals today announced a strategic commercialization partnership with SteinCares, which will gain the commercialization rights for sugemalimab in 10 Latin America countries. 27 January 2025
Biotechnology
Swarm Oncology, a biotech developing novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, has emerged from stealth mode and announced the appointment of Martin Olin as chief executive. 27 January 2025
Pharmaceutical
US pharma giant Pfizer on Saturday announced positive results from the Phase III BREAKWATER trial evaluating its Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. 27 January 2025
Pharmaceutical
The Food and Drug Administration (FDA) last week granted the first approval for UK pharma major AstraZeneca’s Datroway (Dato-DXd) in the USA for the treatment of breast cancer. On his first day back in the White House as President of the USA, last Monday Donald Trump announced he was pulling the country out of the World Health Organization (WHO). US giant Johnson & Johnson kicked off the fourth-quarter financial results reporting season by big pharma last week, with better-than-expected figures.US mRNA vaccines specialist Moderna announced another supply contract for its COVID-19 vaccine with the European Union (EU). 26 January 2025
Biotechnology
US clinical-stage immuno-oncology biotech ALX Oncology Holdings
released positive updated data from the ASPEN-06 Phase II clinical trial demonstrating that its investigational CD47-blocker evorpacept generates a durable clinical response. 25 January 2025
Biotechnology
Sino-American oncology company Shenzhen TargetRx has successfully completed its Series C financing, raising $50 million. 23 January 2025
Pharmaceutical
Chicago-based drug major AbbVie and privately-held San Diego firm Neomorph have announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. 23 January 2025
Biotechnology
A pair of Chinese biotech companies have filed to list on the Hong Kong Stock Exchange. 23 January 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical has received marketing authorization in China from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed innovative humanized monoclonal antibody (MAb) tagitanlimab (formerly KL-A167) used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC). 23 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze